SCHEMBL2424903

SCHEMBL2424903

COC(=O)c1c(C)cc(C(=O)OC(C)(C)C)c(C)c1[N+](=O)[O-]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.42
NR3C2 P08235 1/20 0.40
POLB P06746 2/20 0.38
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CYP3A4 P08684 2/20 0.37
PDGFRB P09619 1/20 0.37
FGFR1 P11362 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT1 P17948 1/20 0.37
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37
ACHE P22303 1/20 0.37
HPGD P15428 2/20 0.35
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HTT P42858 2/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2422846 0.89 SMN1; SMN2 (0.49) SMN1; SMN2POLBALDH1A1MEN1KMT2A
SCHEMBL2428983 0.83 SMN1; SMN2 (0.46) SMN1; SMN2POLBALDH1A1MEN1KMT2A
SCHEMBL2427847 0.78 CYP3A4 (0.42) POLBALDH1A1CYP3A4ACHEHPGD
SCHEMBL2428404 0.78 CYP3A4 (0.41) POLBALDH1A1CYP3A4ACHEHPGD
SCHEMBL27972849 0.78 NPC1 (0.49) SMN1; SMN2ALDH1A1MEN1KMT2ACYP3A4
SCHEMBL27525212 0.75 NR3C2 (0.42) SMN1; SMN2NR3C2POLBALDH1A1MEN1
SCHEMBL28930594 0.75 SMN1; SMN2 (0.49) SMN1; SMN2POLBALDH1A1MEN1KMT2A
SCHEMBL2424860 0.74 CYP3A4 (0.37) POLBCYP3A4ACHEHPGDTSHR
SCHEMBL31455919 0.73 KDM4E (0.41) ALDH1A1CYP3A4PDGFRBFGFR1PDGFRA
SCHEMBL22445779 0.71 SMN1; SMN2 (0.47) SMN1; SMN2POLBALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 SMN1; SMN2 411/4885NR3C2 604/4885POLB 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.